---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-009463"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T16:46:24.671478+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# bioAffinity initiates 2K-patient longitudinal study for CyPath Lung diagnostic

## Summary
- 2,000-patient longitudinal study to evaluate CyPath Lung for early lung cancer detection in high-risk patients with nodules 6-29mm.
- Study will include up to 20 sites, including a dozen VA medical centers and two large military hospitals.
- Earlier trial showed 92% sensitivity, 87% specificity, 88% accuracy in detecting lung cancer in nodules <20mm.
- Enrollment expected up to 18 months; patients followed up to 24 months or until definitive diagnosis.
- Murtha Cancer Center Research Program provides support and funding for federal facilities.

## SEC filing metadata
- accession: 0001493152-26-009463
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226009463/0001493152-26-009463-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226009463/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-009463
- JSON: https://secwatch.observer/filing/0001493152-26-009463.json
- Plain text: https://secwatch.observer/filing/0001493152-26-009463.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.